Vir Biotechnology Inc
NASDAQ:VIR
Intrinsic Value
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. [ Read More ]
The intrinsic value of one VIR stock under the Base Case scenario is 3.45 USD. Compared to the current market price of 7.63 USD, Vir Biotechnology Inc is Overvalued by 55%.
Valuation Backtest
Vir Biotechnology Inc
Run backtest to discover the historical profit from buying and selling VIR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Vir Biotechnology Inc
Current Assets | 1.6B |
Cash & Short-Term Investments | 1.5B |
Other Current Assets | 65.8m |
Non-Current Assets | 330.8m |
Long-Term Investments | 105.3m |
PP&E | 167.2m |
Intangibles | 39.5m |
Other Non-Current Assets | 18.9m |
Current Liabilities | 175.4m |
Accounts Payable | 6.3m |
Accrued Liabilities | 104.2m |
Other Current Liabilities | 64.9m |
Non-Current Liabilities | 153.4m |
Other Non-Current Liabilities | 153.4m |
Earnings Waterfall
Vir Biotechnology Inc
Revenue
|
86.2m
USD
|
Cost of Revenue
|
-2.8m
USD
|
Gross Profit
|
83.4m
USD
|
Operating Expenses
|
-767.7m
USD
|
Operating Income
|
-684.3m
USD
|
Other Expenses
|
69.2m
USD
|
Net Income
|
-615.1m
USD
|
Free Cash Flow Analysis
Vir Biotechnology Inc
VIR Profitability Score
Profitability Due Diligence
Vir Biotechnology Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Vir Biotechnology Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
VIR Solvency Score
Solvency Due Diligence
Vir Biotechnology Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Vir Biotechnology Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VIR Price Targets Summary
Vir Biotechnology Inc
According to Wall Street analysts, the average 1-year price target for VIR is 32.93 USD with a low forecast of 12.12 USD and a high forecast of 115.5 USD.
Ownership
VIR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
VIR Price
Vir Biotechnology Inc
Average Annual Return | 29.34% |
Standard Deviation of Annual Returns | 70.14% |
Max Drawdown | -91% |
Market Capitalization | 1B USD |
Shares Outstanding | 135 032 000 |
Percentage of Shares Shorted | 6.17% |
VIR News
Last Important Events
Vir Biotechnology Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Vir Biotechnology Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 444 full-time employees. The company went IPO on 2019-10-11. The company has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The firm's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. The company is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.
Contact
IPO
Employees
Officers
The intrinsic value of one VIR stock under the Base Case scenario is 3.45 USD.
Compared to the current market price of 7.63 USD, Vir Biotechnology Inc is Overvalued by 55%.